Compare MNDR & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNDR | BJDX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.6M |
| IPO Year | 2023 | 2021 |
| Metric | MNDR | BJDX |
|---|---|---|
| Price | $0.91 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 358.0K | 181.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,040.00 |
| Revenue This Year | $608,852.40 | N/A |
| Revenue Next Year | N/A | $55.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.63 |
| 52 Week High | $5.42 | $10.20 |
| Indicator | MNDR | BJDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 47.61 |
| Support Level | $0.79 | $1.43 |
| Resistance Level | $1.12 | $2.47 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 42.26 | 14.84 |
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services, and the Sale of medicine and medical devices. The majority of the company's revenue is derived from the Telemedicine and other services segment. Geographically, it derives revenue from Singapore.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.